1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €36.54 (+1,607.48%). The median is €36.54 (+1,607.48%).
| Buy |
4 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -7.44M | 4.11% |
| EBITDA | -7.44M | 4.11% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €21.61M |
Number of shares | 9.98M |
52-week high/low | €16.64 - €1.46 |
| Dividends | No |
Beta | 1.27 |
P/E ratio | -0.58 |
PEG ratio | 0.02 |
P/B ratio | 0.84 |
P/S ratio | 0.00 |
Company profile
| Name | Atossa Therapeutics |
| CEO | Steven C. Quay |
| Employees | 16 |
Discover assets
Shareholders of Atossa Therapeutics also invest in the following assets
